Five questions for Friedrich Buck, who is responsible for Geistlich's "Scientific Education" with his team. He himself is a dentist with many years of experience. What current topics are driving him and what dental education offers should you be aware of following the pandemic?
Geistlich Pharma's Surgery business unit becomes the exclusive distribution partner for the NUsurface® meniscus implant in Switzerland and enters into an exclusive partnership with Active Implants. The objective of both companies is to support pain patients by preserving joints.
Last weekend Geistlich once again called for the "Geistlich Charity Walk & Run". The employees came in droves: Participants around the world ran for a donation of 20,955 US dollars. This will benefit a children's dental project in China.
Having started at Geistlich from the beginning of 2021, Dr. Ralf Halbach took the helm as CEO from July. We review his first few months in the company and hazard a guess at what might be expected for Geistlich in the future. Five questions for the new CEO.
As of July 1, 2021, the management of Geistlich Pharma will be newly formed. Paul Note will hand over the controls to his successor Ralf Halbach. Rolf Jeger, Director GRC, and Terance Hart, Director Research, will also leave the Executive Committee due to retirement.
Seven questions about MEFISTO, a Horizon 2020 EU project in which Geistlich is the coordinator of the overall project as well as a scientific partner. Niklaus Stiefel, Group Lead Material Research Biochemistry at Geistlich Pharma, has answers and background information.
The new Geistlich podcast is here. It accompanies you on the journey to our in-house research & development. Immerse yourself in the world of Geistlich, the regeneration specialist, with Dr. Mark Spilker, Geistlich Pharma’s Chief Scientific Officer, and Dr. Marco Zeltner, a specialist in reconstructive dentistry.
After a global slump in sales due to the coronavirus pandemic, Geistlich Pharma rebounded quickly across the board from the middle of the year. The Asia-Pacific region in particular is back on track and showing important momentum for growth. The pandemic and the high value of the Swiss franc continue to present challenges.